Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data.

Curtis JR, Yun H, Lange JL, Matthews R, Sharma P, Saag KG, Delzell E.

Arthritis Care Res (Hoboken). 2012 Dec;64(12):1855-63. doi: 10.1002/acr.21759.

2.

Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.

Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA.

Osteoporos Int. 2011 Mar;22(3):943-54. doi: 10.1007/s00198-010-1309-z. Epub 2010 Jun 8.

3.

Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly.

Butt DA, Mamdani M, Gomes T, Lix L, Lu H, Tu K; Hypertension Outcome, Surveillance Team.

J Bone Miner Res. 2014 Nov;29(11):2483-8. doi: 10.1002/jbmr.2271.

4.

Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.

Olsen KR, Hansen C, Abrahamsen B.

Osteoporos Int. 2013 Oct;24(10):2639-47. doi: 10.1007/s00198-013-2365-y. Epub 2013 Apr 20.

PMID:
23604250
5.

The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial.

Curtis JR, Delzell E, Chen L, Black D, Ensrud K, Judd S, Safford MM, Schwartz AV, Bauer DC.

J Bone Miner Res. 2011 Apr;26(4):683-8. doi: 10.1002/jbmr.274.

6.

Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment.

Modi A, Tang J, Sen S, Díez-Pérez A.

Curr Med Res Opin. 2015 Apr;31(4):767-77. doi: 10.1185/03007995.2015.1016606.

PMID:
25708648
7.

The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.

Wang CC, Lu HT, Dusetzina SB, Wu CH.

J Womens Health (Larchmt). 2016 Jul;25(7):738-46. doi: 10.1089/jwh.2015.5617. Epub 2016 Apr 20.

PMID:
27096405
8.

Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.

Wilk A, Sajjan S, Modi A, Fan CP, Mavros P.

Osteoporos Int. 2014 Dec;25(12):2777-86. doi: 10.1007/s00198-014-2827-x. Epub 2014 Aug 12.

9.

Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.

Cheng LI, Durden E, Limone B, Radbill L, Juneau PL, Spangler L, Mirza FM, Stolshek BS.

J Manag Care Spec Pharm. 2015 Sep;21(9):824-33, 833a.

10.

Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.

Balasubramanian A, Tosi LL, Lane JM, Dirschl DR, Ho PR, O'Malley CD.

J Bone Joint Surg Am. 2014 Apr 2;96(7):e52. doi: 10.2106/JBJS.L.01781.

PMID:
24695929
11.

Treatment for older men with fractures.

Shepherd AJ, Cass AR, Ray LA, Tan A, Wilkinson GS.

Osteoporos Int. 2012 Mar;23(3):1041-51. doi: 10.1007/s00198-011-1681-3. Epub 2011 Aug 3.

PMID:
21811867
12.

Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study.

Kim SC, Kim MS, Sanfélix-Gimeno G, Song HJ, Liu J, Hurtado I, Peiró S, Lee J, Choi NK, Park BJ, Avorn J.

Am J Med. 2015 May;128(5):519-26.e1. doi: 10.1016/j.amjmed.2015.01.014. Epub 2015 Feb 3.

13.
14.

Fractures and mortality in relation to different osteoporosis treatments.

Yun H, Delzell E, Saag KG, Kilgore ML, Morrisey MA, Muntner P, Matthews R, Guo L, Wright N, Smith W, Colón-Emeric C, O'Connor CM, Lyles KW, Curtis JR.

Clin Exp Rheumatol. 2015 May-Jun;33(3):302-9. Epub 2014 Jul 28.

PMID:
25068266
16.

Proportion of osteoporotic women remaining at risk for fracture despite adherence to oral bisphosphonates.

Imel EA, Eckert G, Modi A, Li Z, Martin J, de Papp A, Allen K, Johnston CC, Hui SL, Liu Z.

Bone. 2016 Feb;83:267-75. doi: 10.1016/j.bone.2015.11.021. Epub 2015 Dec 2.

PMID:
26657827
17.

Bisphosphonate use and subsequent hip fracture in South Korea.

Lee YK, Ha YC, Choi HJ, Jang S, Park C, Lim YT, Shin CS.

Osteoporos Int. 2013 Nov;24(11):2887-92. doi: 10.1007/s00198-013-2395-5. Epub 2013 May 17.

PMID:
23681088
18.

The complex relation between bisphosphonate adherence and fracture reduction.

Patrick AR, Brookhart MA, Losina E, Schousboe JT, Cadarette SM, Mogun H, Solomon DH.

J Clin Endocrinol Metab. 2010 Jul;95(7):3251-9. doi: 10.1210/jc.2009-2778. Epub 2010 May 5.

19.

Bisphosphonate use and risk of post-operative fracture among patients undergoing a total knee replacement for knee osteoarthritis: a propensity score analysis.

Prieto-Alhambra D, Javaid MK, Judge A, Maskell J, Kiran A, Cooper C, Arden NK.

Osteoporos Int. 2011 May;22(5):1555-71. doi: 10.1007/s00198-010-1368-1. Epub 2010 Aug 7.

PMID:
20694456
20.

Decision to take osteoporosis medication in patients who have had a fracture and are 'high' risk for future fracture: a qualitative study.

Sale JE, Gignac MA, Hawker G, Frankel L, Beaton D, Bogoch E, Elliot-Gibson V.

BMC Musculoskelet Disord. 2011 May 9;12:92. doi: 10.1186/1471-2474-12-92.

Supplemental Content

Support Center